Choose injectable BPC-157 if: Your target is a tendon, ligament, joint, or muscle injury You need systemic anti-inflammatory or tissue repair effects Speed and reliability of delivery matter You are working within a structured peptide therapy protocol with a licensed provider Choose oral BPC-157 if: Your primary concern is gut health leaky gut, IBD, IBS, gastric ulcers You want high local GI concentrations, not systemic distribution You prefer non-invasive administration for long-term or maintenance use You are combining BPC-157 with another systemic peptide therapy Consider nasal delivery only if: Neurological applications are the clinical focus A licensed provider explicitly recommends it based on your presentation Injection is contraindicated and oral delivery is insufficient Do not choose a delivery method based on convenience alone
Yes, in people with B12 deficiency, injections can quickly improve energy and reduce fatigue
As nitric oxide signaling and antioxidant activity become enhanced, secondary inflammation reduces
Key Takeaways The global market was valued at USD 150 million in 2022, projected to reach USD 230 million by 2030
Compounded medications are not FDA-approved
AOD 9604 has been studied for its ability to trigger fat metabolism and support joint tissue repair